Slide 1

765 / 1631

Evolving Standards of Care in Non-Hodgkin’s Lymphoma
Guideline Recommendations for Treatment of Relapsed
DLBCL
▪ Second-line therapy in candidates
for high-dose therapy + ASCT
– DHAP ± rituximab
– ESHAP ± rituximab
– GDP ± rituximab
– GemOx ± rituximab
– ICE ± rituximab
– MINE ± rituximab
▪ Second-line therapy for patients who
are not candidates for high-dose
therapy
– Clinical trial
– Rituximab
– CEPP ± rituximab
– Lenalidomide
– EPOCH ± rituximab
NCCN practice guidelines in oncology: non-Hodgkin’s lymphomas V.1.2010.
Available at: